ATARA Biotherapeutics supplements prospectus for stock offering

ATARA Biotherapeutics Inc. (NASDAQ: ATRA) filed a prospectus supplement that allows the company to continue offering common stock under its existing sales agreement despite changes in regulatory requirements.

The biotechnology company filed the second supplement to its sales agreement prospectus following a Securities and Exchange Commission staff interpretation published March 19, 2026. The interpretation addresses situations where companies may continue at-the-market offerings even when they no longer meet certain public float requirements.

Under the updated prospectus, ATARA may offer and sell shares with an aggregate offering price of $79,269,007, representing the full amount remaining available under its sales agreement with TD Securities (USA) LLC. The sales agreement, originally dated November 1, 2023, was established when TD Securities succeeded Cowen and Company LLC as the sales agent.

The SEC staff interpretation permits companies to continue selling securities under previously filed prospectus supplements even if they subsequently fail to meet the $75 million public float requirement, provided they remain eligible to use Form S-3 under alternative provisions and had reasonable expectations to sell the securities when the agreement was established.

The supplement modifies ATARA's original sales agreement prospectus dated November 13, 2023, which was previously amended in March 2026. The company's common stock trades on the Nasdaq Global Market under the symbol "ATRA."

You May Also Be Interested In

• ROMA Green Finance signs $15M letter of intent for 5% stake in NXTGrid
• Robinhood prices $2B convertible notes offering due 2029
• Iridium launches hybrid IoT module combining satellite and cellular